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The majority of high-grade serous ovarian carcinoma cases are detected in advanced stages
when treatment options are limited. Surgery is less effective at eradicating the disease
when it is widespread, resulting in high rates of disease relapse and chemoresistance.
Current screening techniques are ineffective for early tumor detection and consequently,
BRCA mutations carriers, with an increased risk for developing high-grade serous ovarian
cancer, elect to undergo risk-reducing surgery. While prophylactic surgery is associated
with a significant reduction in the risk of cancer development, it also results in surgical
menopause and significant adverse side effects. The development of efficient early-stage
screening protocols and imaging technologies is critical to improving the outcome and
quality of life for current patients and women at increased risk. In addition, more accu-
rate animal models are necessary in order to provide relevant in vivo testing systems and
advance our understanding of the disease origin and progression. Moreover, both geneti-
cally engineered and tumor xenograft animal models enable the preclinical testing of novel
imaging techniques and molecularly targeted therapies as they become available. Recent
advances in xenograft technologies have made possible the creation of avatar mice, person-
alized tumorgrafts, which can be used as therapy testing surrogates for individual patients
prior to or during treatment. High-grade serous ovarian cancer may be an ideal candidate for
use with avatar models based on key characteristics of the tumorgraft platform.This review
explores multiple strategies, including novel imaging and screening technologies in both
patients and animal models, aimed at detecting cancer in the early-stages and improving
the disease prognosis.
Keywords: fallopian tubal secretory epithelial cell, high-grade serous carcinoma, genetically engineered mouse
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TREATMENT APPROACHES FOR PATIENTS AND HIGH-RISK
WOMEN
Ovarian cancer is the most lethal gynecological malignancy, with
the majority of high-grade serous carcinoma (HGSC) cases being
diagnosed in late stages of disease [for a comprehensive review see
Bast (1)]. The current American Cancer Society statistics estimates
that the 5-year survival is 44% when all disease stages are included
but declines to 25% if only advanced stage cases are considered
(1–3). Initial treatment for HGSC patients involves debulking
surgery, which typically includes a combination of hysterectomy,
bilateral salpingo-oophorectomy, and removal of the omentum,
followed by therapy using platinum compounds and taxanes (4, 5).
While platinum-based chemotherapy improves patient survival,
the treatment is also very toxic; in addition, disease relapse follow-
ing treatment and the acquisition of platinum chemoresistance
are frequent events, suggesting a need for alternative treatment
Abbreviations: FR-α, folate receptor α; FTSEC, fallopian tubal secretory epithe-
lial cell; GEMM, genetically engineered mouse models; HGSC, high-grade serous
carcinoma; NIRF, near-infrared fluorescence; STIC, serous tubal intraepithelial
carcinoma; TCGA, the Cancer Genome Atlas.
modalities (6). One strategy involves the addition of bevacizumab,
a monoclonal antibody targeting VEGF-A, which has been tested
together with standard chemotherapy in the setting of platinum-
resistant recurrent disease. Indeed, the combination of an anti-
angiogenic compound and single-agent chemotherapy improved
objective response rates and progression free survival in compar-
ison with chemotherapy alone, but the overall survival trend was
not significant (7). An alternative strategy, which is aimed at reduc-
ing both the treatment toxicity and recurrence rates, proposes the
administration of lower doses of carboplatin plus paclitaxel given
once a week for 18 weeks instead of standard doses administered
every 3 weeks for six cycles. Interestingly, this modified weekly reg-
imen of reduced chemotherapeutic doses has recently been found
to not only be an effective option for first-line treatment but, most
importantly, to be associated with an enhanced quality of life as
assessed physically, socially, emotionally, and functionally (8).
New treatment approaches could be beneficial not only for
patients but also for women at increased risk for developing
the disease. A recent study, which included a broadly span-
ning, exome-wide analysis of both ovarian cancer somatic and
germline mutations, has estimated that more than 20% of women
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likely have an inherited predisposition to ovarian cancer (9).
The most studied mutations involve the BRCA family of tumor
suppressor genes, which confer an increased risk for developing
breast and ovarian cancers (10). The lifetime risk for devel-
oping breast cancer in BRCA mutation carriers varies between
56 and 84% while the ovarian cancer risk ranges from 36–
46% to 10–27% for women with BRCA1 and BRCA2 muta-
tions, respectively (11). In addition, lifetime risks for both breast
and ovarian cancers due to BRCA mutations appear to have
increased over time, possibly due to lower physical activity
and higher BMIs (12). When assessing individual patient risks
for ovarian cancer it is important to note that irrespective of
genetic risk, women with irregular menstrual cycles experience
a 2.4 times greater incidence of death due to ovarian cancer
(13).
QUALITY OF LIFE AFTER PROPHYLACTIC SURGERY IN
HIGH-RISK WOMEN
The mean age at the time of diagnosis for the average population is
63 years; by comparison, the mean age for BRCA mutation carri-
ers is considerably lower at 50.8 years. For both groups, the cancer
risk increases with age, especially after menopause. Consequently,
the current recommendation for BRCA carriers is to undergo
risk-reducing surgery once childbearing is completed, since they
tend to be diagnosed at an earlier age than sporadic ovarian can-
cer (14). Standard prophylactic surgical options include bilateral
mastectomy and salpingo-oophorectomy, which confer the most
substantial reduction in cancer risk and increase in life expectancy
(10, 15, 16). Studies looking at the efficacy of bilateral prophylac-
tic salpingo-oophorectomy in BRCA mutation carriers concluded
that it not only resulted in a 96% reduction in the risk of devel-
oping coelomic epithelial cancers but also decreased the breast
cancer risk by 53% in comparison with BRCA mutation carriers
who chose not to undergo the procedure (14). Despite the drastic
risk-reduction associated with prophylactic surgery, it is far from
an ideal treatment approach. In addition to being stripped of their
inherently female characteristics, women who choose to undergo
a combination of mastectomy, bilateral salpingo-oophorectomy,
and hysterectomy are faced with a significant decrease in their
quality of life, premature menopause, hot flashes, decreased cog-
nition and sexual function, and increased risk of osteoporosis and
cardiac mortality (14, 17–19). The use of hormone therapy and
other medications may mitigate some of these adverse effects.
Nevertheless, hormone replacement therapy is controversial, espe-
cially in high-risk women, as it has been linked to an increased
risk of breast cancer (20). While an elective oophorectomy pro-
cedure may correlate negatively with life expectancy in women
at average risk, the procedure remains beneficial for women at
increased risk (21). Despite the possible negative physiological
and psychological impacts of prophylactic oophorectomy, women
at increased risk for developing HGSC report less anxiety about
developing the disease, which they believe compensates for unde-
sirable side effects (16). The primary cause of depression reported
amongst post-surgical women is due to sexual dysfunction (21).
In addition, BRCA mutation carriers may also experience the fear
of transmitting a hereditary disease to their children. Women with
these reproductive concerns could choose to investigate alternative
methods, including in vitro fertilization and screening of embryos
via preimplantation genetic diagnosis in order to eliminate the
chance of transmitting faulty BRCA genes to their children (17).
NON-SURGICAL RISK-REDUCTION APPROACHES IN BRCA
MUTATION CARRIERS
There are limited risk-reducing approaches for women withBRCA
mutations who choose not to undergo prophylactic surgery (22).
Current strategies include early breast cancer screening consisting
of annual mammogram and breast MRI. In addition, gynecologic
cancer screening consists of baseline transvaginal ultrasound and
CA-125 serum level measurements followed by frequent moni-
toring using ROCA evaluation protocols. Breast cancer screening
results in early tumor detection and a survival advantage; in con-
trast, ovarian cancer screening has yet to be associated with a
significant reduction in mortality (23). For example, 63% of ovar-
ian cancers detected were stage IIC or higher in a comprehensive
study of over 6000 high-risk women (23). This can be partially
attributed to the fact that current screening options are limited
and not best suited to detect early-stage cancers (24). An alternative
strategy involves the use of chemopreventive methods, including
selective estrogen receptor inhibitors, tamoxifen and raloxifene,
in addition to oral contraceptives (15). Oral contraceptives have
indeed been shown to decrease the risk of developing ovarian
cancer in the general population (25). However, the use of oral
contraceptives in BRCA mutation carriers, while beneficial for
ovarian cancer prevention, may be associated with an increased
risk for developing breast cancers (26, 27).
DEVELOPMENT OF IMAGING TECHNOLOGIES AIMED AT
EARLY DETECTION AND IMPROVING PATIENT OUTCOME
As mentioned above, the vast majority of both familial and spon-
taneous HGSC cases are diagnosed in advanced stages, at which
point the prognosis is poor (28). Because there are few clear early
symptoms, developing effective methods for early detection is
paramount to improving long-term patient survival (29). Cur-
rent methods of detection include non-invasive screenings using
serum CA-125, ultrasound, sonography, CT, and MRI scans (30,
31). A laparoscopic procedure may also be used to provide an
image of the lower abdominal organs, as well as attain a biopsy,
which is necessary in order to confirm cancer diagnosis. These
tools can give information regarding the size, composition, and
location of the tumor and whether it has spread, which will be
important for disease staging and treatment plans (28, 32). In
terms of early detection, it is important to note that current imag-
ing technologies are not able to distinguish precursor lesions inside
the fallopian tube or ovary, two of the tumor initiation sites for
HGSC. Novel in vivo imaging devices, such as confocal microla-
paroscopes, which are instrumental in providing live images of
abnormal regions and guiding biopsies, may be better equipped to
assist with early tumor diagnosis (33). Images obtained by these
probes in real-time during surgery have shown a clear distinc-
tion between normal and abnormal regions within the ovarian
surface epithelium (33). Furthermore, studies using a flexible
microlaparoscope have demonstrated the ability to provide high-
resolution images of early stage cancer inside the fallopian tube
in the intra-operative setting, thereby facilitating both an earlier
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diagnosis and accurate disease staging (34). Since these procedures
have shown merit in surgical settings, they may become a viable
complementary option to traditional biopsies as future modali-
ties of disease confirmation (33). Nevertheless, the specificity and
sensitivity of this method have yet to be determined in clinical
trials and there are also drawbacks associated with this procedure.
For example, the image quality produced by the microlaparoscope
is diminished when compared to traditional laparoscopes due to
a smaller scope size, focal distance, and a reduced light output.
Procedural complications may also arise from a lack of tight cor-
relation between the movement of the instrument handle and
instrument movement in the surgical field due to its increased flex-
ibility (35). Other considerations include a reduced imaging depth,
which may limit the ability to view cells below the tissue surface
layer, as well as the development of non-toxic and non-mutagenic
contrast-enhancing agents (33). Nevertheless, the device can suc-
cessfully image organs in vivo without major complications (33)
and needs to be carefully evaluated in future clinical trials.
Another widely used primary diagnostic tool for women seek-
ing evaluation of a pelvic mass is transvaginal sonography (TVS).
Traditional TVS technologies are being replaced by contrast
enhanced transvaginal sonography (CE-TVS) and transvaginal
color Doppler sonography (TV-CDS), which can better depict
the tumor morphology by analyzing its microvasculature (31).
In a study aimed at evaluating the diagnostic ability of contrast
enhanced 3-dimensional power Doppler sonography (CE-3D)
relative to conventional 3D Doppler sonography, the CE-3D tech-
nology showed 95.6% accuracy in distinguishing between benign
and cancerous tumors compared to 86.7% accuracy for the con-
ventional method (36). Contrast-enhancing agents coupled with
transvaginal and Doppler sonography may merit further investi-
gation as an early screening tool for women at risk. It is worth
mentioning that the development of selective means for tumor
imaging is critical not only for early detection but also for improv-
ing patient outcome (29). Thus, the use of selective intraoperative
tumor imaging devices has the potential to both improve dis-
ease staging and enhance precision during cytoreductive surgery
as it allows for better visualization of tumors (37). For example,
a combination of functional in vivo and anatomical ex vivo X-ray
micro-computed tomography (µCT) can provide a highly detailed
three-dimensional analysis of the tumor micromorphology, vas-
cularization, and accurately quantify relative blood volumes (rBV)
in tumors, which can further inform treatment plans (38). Most
importantly, the study has found a direct correlation between
microvascular parameters (i.e., vessel size, the complexity of vessel
branching) and tumor angiogenesis and aggressiveness (38).
Further advances have been made in ultrasound technology
as well. Photoacoustic imaging is an emerging technology based
on the photoacoustic effect, which is generated when tissues are
pulsed with non-ionizing lasers. This results in a transient ther-
moelastic expansion and emission of an acoustic wave, which
is detected by ultrasonic transducers and converted into images
(39). A study evaluating biodegradable photoacoustic imaging
agents in animal models of ovarian cancer found that cellulose
nanoparticles produced high contrast signals. Interestingly, cellu-
lose nanoparticles demonstrated a significant increase in signal
when compared to gold nanoparticles, which are commonly used
in photoacoustic imaging. Unfortunately, this imaging agent only
proved to be biodegradable ex vivo. For the purpose of reduc-
ing toxicity and to facilitate clinical translation, further research
will need to focus on nanoparticles that biodegrade within the
mammalian circulatory system (40).
A strong emphasis is currently placed on evaluating imaging
agents that are safe to use in patients and allow the visualization
of early or recurrent tumors. Current research in ovarian cancer
investigates the use of the folate receptor α (FR-α) and HER-2
as targeted agents for tumor-specific fluorescence imaging. Thus,
FR-α is overexpressed in the majority of epithelial ovarian can-
cers, especially in HGSC tumors with a high risk of recurrence.
Increased FR-α expression is detected not only in primary tumors
but also in metastatic foci and recurrent tumors (41). Most impor-
tantly, chemotherapy does not appear to significantly alter FR-α
expression in patient tumors (37, 41). In addition, FR-α-targeted
fluorescent agents are able to selectively enhance imaging of tumor
cells (37). PPF, an FR-targeted probe that is well suited for both
PET and optical imaging was investigated in vivo in a trial using
primary cell xenografts, in vitro with primary human ovarian can-
cer cells, and ex vivo with omentum removed from xenografts (42).
PPF injected either intraperitoneally or intravenously was able to
identify FR-positive primary HGSC tumors and their metastases
to the omentum. As FR is overexpressed in HGSC, FR-targeted
probes, such as PPF, may bear great utility in the clinical setting.
This method could be ideal for guiding surgery due to the non-
invasive, high-resolution, real-time images it produces (42). The
unique features of this novel imaging tool may prove useful for
ovarian cancer detection and monitoring. Furthermore, fluores-
cence imaging using FR-α-targeted agents could play a critical role
during debulking surgery, as current methods of imaging are not
tumor-specific.
Fluorescence imaging has been shown to detect a greater num-
ber of tumors when compared to conventional methods. Inter-
estingly, a vinblastine folate-targeted drug, vintafolide, when used
in combination with a diagnostic imaging tool, etarfolatide, may
merit attention as a means to advance personalized treatments.
Thus, etarfolatide imaging has been used successfully to select
patients with FR-positive platinum-resistant ovarian tumors who
may benefit from folate-targeted therapy (43). This novel combi-
nation of folate-targeted agents for imaging and treatment resulted
in a marked increase in progression free survival for platinum-
resistant patients. Based on the highly selective nature of this
treatment, the drug efficacy was reported to be greater and its tox-
icity decreased compared to standard therapy (43). An alternative
strategy for selective tumor imaging involves the use of the HER-2
biomarker, which is overexpressed in advanced HGSC cases (44).
Imaging using HER-2-targeted magnetic iron oxide nanoparticles
allows both magnetic resonance and optical imaging of peritoneal
tumors when used in orthotopic ovarian xenograft models (45).
This technology, which enables tumor imaging with high speci-
ficity and resolution, can be instrumental in drug delivery and
image-guided surgery (44, 45). A third strategy involves the devel-
opment of near-infrared fluorescence (NIRF) imaging technolo-
gies, which have been successfully tested in vivo in both pancreatic
and ovarian cancer models as an alternative to ultrasound, CT,
and MRI scans (46). Gene expression profiling was instrumental in
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identifying proteases relevant to tumors, which further enabled the
development of protease-specific NIRF probes. Such probes can
provide not only a higher resolution for molecular-guided detec-
tion of early tumors but also the ability to distinguish between
inflammation and cancer (46). Similarly, an alpha(v)beta(3-)
integrin targeted NIRF probe was used successfully in ovarian
xenograft models to optimize debulking surgery (47). Further-
more, the increased target to background ratio, high sensitivity
(95%), specificity (88%), and diagnostic accuracy (96.5%) of this
imaging system suggest that the NIRF-targeted platform is well
suited for clinical translation and may be able to provide highly
accurate images of small tumor lesions that are otherwise difficult
to detect (47).
Plasma tumor biomarkers for the detection of early tumors
and precursor lesions have been difficult to identify. CA-125 is
presently used to help diagnose ovarian cancer, mainly for late
stage cases, and to predict the chance of tumor recurrence (48).
Nevertheless, CA-125 is not always a reliable biomarker for early
stage tumors due to its lack of sensitivity (48). Large screening
studies are currently underway to determine the sensitivity and
specificity of a combined monitoring protocol using serum CA-
125 levels and TVS for early diagnosis. The screening is based on
an improved algorithm designed by Dr. Steven Skates to identify
cancer risk based on rising trends in individual CA-125 levels (1).
An alternative strategy involves the combined evaluation of mul-
tiple biomarkers in addition to CA-125. Research suggests that the
addition of HE4, leptin,prolactin,osteopontin, insulin-like growth
factor-II, CEA, and soluble vCAM cancer biomarkers to CA-125
serum surveillance protocols may result in a better diagnostic reli-
ability when compared to CA-125 alone (1, 25). It is worth noting
that recent studies suggest that a significant proportion of HGSC
tumors originate from precursor lesions [serous tubal intraepithe-
lial carcinoma (STIC)] located within the fallopian tube rather
than the ovary, and this is the case especially in BRCA women
(1, 49). Consequently, the development of serum screening tests
and methods of diagnostic imaging need to include markers char-
acteristic for the fallopian tube/fimbria in addition to the ovary.
Currently, small early tumors within the fallopian tube cannot
be detected via ultrasound or by measuring serum CA-125 levels
(50). Comprehensive screening of such lesions through endome-
trial cytological testing may be a promising method for the early
detection of HGSC in high-risk women and BRCA mutation carri-
ers. Otsuka et al. reported that tumor cells shed from tubal STICs
could be detected through careful examination of endometrial
cytological samples (50). This would enhance the early detection
rates for HGSC tumors as the occurrence of false positives through
cytological testing appears to be low (50). Interestingly, this pilot
study was able to detect malignant cells in five patients for whom
imaging results were normal; three of them presented with no
symptoms and were later diagnosed with early-stage HGSCs (50).
In addition to further confirming the tubal site of origin for HGSC
cases, the study also reported a 4-fold increase in the number of
high-grade serous tumors being detected using this method when
compared to other ovarian cancer subtypes (50). In contrast, the
direct testing of cervicovaginal cytological samples yielded posi-
tive results in only one of five patients, suggesting that this is not
an efficient means of detecting early-stage HGSC tumors.
GENERATION OF IMPROVED ANIMAL MODELS THAT
CLOSELY RESEMBLE HGSC
In addition to aiding in the development of new imaging tech-
niques, murine models of ovarian cancer are integral to drug
development and disease pathogenesis studies (46, 51). While sev-
eral genetically engineered mouse models (GEMM) have been
previously developed for endometrioid ovarian cancer (52–54),
clinically relevant models for HGSC have been difficult to gener-
ate. This could be due to model designs based solely on a traditional
view of disease pathogenesis, such as the ovarian origin hypothe-
sis. New clinical protocols, which involve the sequential sectioning
and examination of the fimbrial (SEE-FIM) end of the fallopian
tube pioneered by Dr. Christopher Crum, have identified precur-
sor lesions for HGSC arising in secretory cells of the fallopian
tube, namely p53 signatures and STICs (55–58). In addition, sev-
eral groups have been instrumental in leading efforts for refining
murine HGSC models. Recently, the first genetic model of de
novo HGSC originating in fallopian tubal secretory epithelial cells
(FTSEC) has been generated, which recapitulates key genetic alter-
ations (BRCA, TP53, and PTEN ) and precursor lesions (STICs)
that are hallmarks of the human disease (59). In addition to
offering mechanistic insight into the origin and pathogenesis of
HGSC, this model provides a platform to explore tumor sensitiv-
ity to novel therapeutic agents and diagnostic imaging methods
that include the distal fallopian tube in addition to the ovary
(59). Recently, a second genetically engineered model of HGSC
was described using the Ovgp-1 promoter to target SV40 large
T-antigen-induced tumorigenesis in the fallopian tube (60). This
model also displays neoplastic lesions of the fallopian tube that
resemble human STICs and p53 signatures. The murine ovarian
carcinomas have molecular characteristics that strongly resem-
ble the human disease as well. Furthermore, gene expression
analysis studies of Ovgp-1-driven tumors have identified a novel
biomarker, topoisomerase II-alpha, which is overexpressed with
mutant TP53 in both murine and human STICs and HGSCs but
not in normal adjacent tissues (60). Most importantly, this model
provides independent support for the hypothesis that HGSC may
be primarily tubal in origin and mirrors the clinical progression
of human HGSCs (61). The development of FTSEC-driven ani-
mal models will be instrumental in providing a platform to test
newly emerging data from The Cancer Genome Atlas (TCGA) in
an in vivo relevant system. The goal of the research community
is to develop ovarian cancer models that recapitulate not only
novel genetic/genomic alterations but also the histopathology and
clinical behavior of HGSCs. Resolving the pathogenesis of HGSC
and its precursor lesions will likely enable more efficient meth-
ods for early detection, tumor imaging, and cancer prevention.
Furthermore, by using a combination of murine model studies
and epidemiological data from patients, it will be important to
determine if premenopausal women with BRCA mutations can
be offered risk-reduction surgery in a multi-step procedure with-
out undergoing surgical menopause and loss of fertility in their
younger years.
As a complement to genetically engineered models, person-
alized patient-derived murine xenografts (“avatar mice”) have
been developed, which are able to more accurately predict tumor
responses to therapy. Xenograft tumor models have been used
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for decades to examine the behavior of various types of thera-
pies within a living system (62). They can closely resemble the
molecular and histological characteristics of the human cancer
they are derived from (63, 64) and demonstrate clinical rele-
vance by predicting the activity and effects of trial therapies (65).
However, their predictive ability varies dramatically based on the
cancer being studied, and multiple therapies, which tested well
in xenografts, did not ultimately result in successful clinical tri-
als (66–68). While traditional xenografts are created by generating
and then engrafting established cell lines (51), a subcategory of
xenografts produced by direct transfer of patient tumor tissue into
immunocompromised mice (also known as explant xenografts or
tumorgrafts) has mimicked the drug effects seen in humans much
more closely than cell line xenografts (69). Furthermore, one study
of personalized tumorgrafts involving a broad range of human-
derived tumors and anticancer therapies demonstrated a positive
clinical predictive value for drug resistance over 90% of the time
(70). Unlike human cell cultures, which tend to result in increas-
ingly homogenous populations with successive passages, direct
tissue transplants more accurately represent the heterogeneous
makeup and genetic diversity of the original tumor, including
its relative cell proportions and overall genomic profile (71, 72).
These tumor sections can be implanted orthotopically within the
homologous source tissue in addition to being dispersed into the
body cavity via intraperitoneal injection, as is the case for cell line
xenografts (73, 74). Using these techniques, avatar models have
been generated that closely recapitulate the tumor of a specific
donor patient. This has led to the identification of personalized
therapeutic regimens by creating a tailored stand-in for patient
tumors prior to or alongside treatment (75). The use of tumor-
graft testing surrogates, which are generated by using a specific
patient’s own tissue, has increased over the last decade. This trend
was initiated by a recent study that described the use of xenograft
technologies to create personalized tumorgrafts for a total of 14
patients with a variety of cancer types (76). The study results iden-
tified optimal, non-obvious treatment choices with a high rate of
clinical success (76). This process has been performed with simi-
lar success in models of lung (77), pancreatic (78), prostate (79),
breast (80, 81), and fallopian tube (82) cancers. In addition to
being highly representative of the morphology and progression of
human cancers, it was found that the success of tumor engraftment
is by itself a prognostic indicator of disease outcome for women
with newly diagnosed breast cancer (80).
While GEMM and xenografts both strive to generate accurate
models of human disease and their usage at times overlaps, they
have individual features best suited to distinct roles in cancer
research. Tumors that develop from a xenograft retain the nat-
ural genetic alterations derived from the original source (63, 83).
Conversely, GEM models must recreate these changes based on
the result of investigation or hypothesis, and therefore they often
cannot replicate the complexity and genomic diversity found in
patient tumors (74). In cancers with high variance in molecu-
lar alterations between patients, tumorgrafts should be used to
test therapies in models that more accurately represent individ-
ual tumors (77), since generalized results from GEMM studies
will not be applicable. Personalized tumorgrafts have also been
used to identify changes in drug resistance at specific stages of
disease by grafting repeatedly from the same patient at different
time points (63). Furthermore, avatar models could also allow the
preemptive identification of new treatment strategies necessary
when a patient develops resistance to clinically available therapies
(84). Being able to determine tumor sensitivity and drug resis-
tance for each individual patient upfront would allow oncologists
to attempt experimental treatments with a higher probability of
success while retaining conventional therapies as an option (85).
In contrast, GEMMs have attributes superior to avatar models
when it comes to studying the origin of the disease, precursor
lesions, tumor progression, and the contribution of the immune
system to cancer pathogenesis by allowing the inducible target-
ing of key genes in a tissue-specific manner in immunocompetent
mice (86). There are several challenges in creating avatar mice rela-
tive to GEM and cell line xenograft models, including the need for
surgical extraction of adequate tumor samples from the patient,
ideally including accessory tissue (72), and a high rate of implan-
tation failure (85). While tumor heterogeneity is represented, the
microenvironment is typically not. This drawback, combined with
the use of immunocompromised mice, restricts how similarly
avatar models behave when compared to human disease. Such
limitations could be overcome by incorporating recent xenograft
advancements. The tumor microenvironment can be retained in
a xenograft by grafting stroma alongside the tumor (75) and the
use of “humanized”models preserve immune system functionality
after engraftment (87). Besides technical concerns, there is a high
financial barrier for creating new avatar lines (75). However, once
tissues have been extracted and implanted, human tumors can be
serially passaged in mice, archived, and later repropagated from
tumor banks (82). The generation of tumor banks enables the
repeated testing and study of patient tumors from a small number
of original extractions.
Further development of representative mouse models of HGSC
is an urgent need for the field (88) and tumorgrafts have attrib-
utes suited to this subtype. HGSCs are characterized by rapid
metastasis (89) and tumorgraft models were reported to metas-
tasize to regions similar to those seen in patients (90). HGSCs
are also characterized by genomic instability (51) and tumor-
grafts were shown to accurately retain the genomic profile of the
original patient sample in animal models throughout multiple
grafts (72). Avatar mice have been generated for fallopian tube
carcinoma (82), which supports their viability for ovarian can-
cer, particularly in conjunction with the tubal origin hypothesis
(91). This year, the first large-scale tumorgraft mouse study of
ovarian cancer was published, consisting of 168 engrafted mod-
els from patient samples, which were representative of the entire
spectrum of the disease (83). As in previous tumorgraft stud-
ies, the models closely resembled the patients they were derived
from. The majority of models that developed ascites originated
from patients with ascites, which is notable as the development of
ascites is characteristic of HGSC (89). Consistent with prior com-
parisons between cell line xenografts and donor patient platinum
sensitivity in ovarian cancer (92), all of the ovarian models tested
for platinum sensitivity had the same type of response as the donor
patient (83). It has been suggested that the tumor microenviron-
ment may play a role in the high rate of relapse and increased drug
resistance seen in HGSC (93). These ovarian tumorgrafts strongly
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resemble the source microenvironment by inducing the formation
of tumor stroma (83). As shown in a larger tumorgraft study (72),
the ovarian models closely resembled the source patient’s genomic
alterations after engraftment and the grafts implanted in clinically
relevant sites. Finally, just as demonstrated previously (80), the
initial success of a graft tended to correlate negatively with patient
survival (83). This extensive study demonstrates the feasibility of
ovarian tumorgrafts as patient surrogates, particularly given the
reasonably accurate representation of the disease diversity (94).
Consequently, the generation of avatar mouse models for HGSC
is expected to assist oncologists with establishing individual resis-
tance profiles quickly in a surrogate model following biopsy and
informing patients of therapy choices in real-time (85).
Avatar tumorgrafts have been found to be highly predictive
models clinically and the generation of such models can aid with
drug design on an individual patient basis (67, 76). The use of
avatar models alongside patients in concurrent clinical trials has
already been proposed (75), though it is noted that variance in
how accurately these strains reflect human disease, including the
contribution of the immune system, can be a confounding fac-
tor. In recent years, there has been renewed interest in harnessing
the immune system to target cancers (95, 96), often achieved by
blocking the inhibitors of immune reactions elicited by tumor
cells. This approach has led to considerable success, such as the
use of ipilimumab immunotherapy in metastatic melanoma (96).
Ipilimumab is a monoclonal antibody against CTLA-4 and pro-
motes effective antitumor targeting by cytotoxic T lymphocytes.
Therapies targeting CTLA-4 have also been investigated in ovarian
cancer; a combined treatment, which involves blockade of CTLA-
4 and PD-1 and boosts the immune system, was found to induce
tumor rejection in 75% of tumor models examined (97). In addi-
tion, the endothelium of many tumors may function as a primary
defense against immune system activation by creating a physi-
cal protective barrier for the tumor and resisting immune cell
invasion (98). It remains to be seen whether the development of
effective immunotherapies will increase the efficacy of conven-
tional therapies and achieve durable remissions in patients (96).
Notably, it was recently demonstrated that traditional therapeutic
regimens could be modified to effectively recruit the immune sys-
tem in the setting of platinum-resistant relapsed disease (6). While
platinum and paclitaxel are often delivered at maximum tolera-
ble doses, the dose-dense chemotherapy study demonstrates that
delivery of conventional drugs in low doses within frequent inter-
vals can enhance natural antitumor immune responses and reduce
immunosuppression, thus leading to increased treatment efficacy
(6). Thus, a dose-dense chemotherapy regimen was successful in
promoting the antitumor CD8+ T-cell response in both mouse
models and patients and reduced the tumor ability to suppress the
immune system. This bodes well for further optimization of such
treatments for individual needs,particularly as an extended weekly,
dose-dense carboplatin and paclitaxel regimen has been shown to
be effective in heavily pre-treated, recurrent, platinum-resistant
ovarian cancer patients (99). Clearly, optimizing these treatments
for patients requires a clinically translatable graft model. Xenograft
models with an implanted functional human immune system have
been previously developed to investigate viral and immune disease
(100). Interestingly, such models were shown to be functional
in cancer as well (87). A key benefit of GEMMs over xenografts
has always been that they retain normal immune function (51).
However, a xenograft with a humanized immune system, which
is interacting with human tumor cells, may be more translatable
to designing immunotherapies for patients based on individual
needs. While GEMMs may ultimately prove more useful than
avatar models for understanding the intricate details of HGSC
origin and progression, personalized tumorgrafts will be key for
the design of individual therapeutic regimens.
CONCLUSIONS
Advances in tumor screening and imaging may help determine
the optimal time to employ risk-reducing surgical approaches in
women at high risk for HGSC, including BRCA mutation car-
riers. Prophylactic surgery offers the most significant reduction
in the risk of developing breast and ovarian cancers, as current
surveillance methods are not effective enough to lend support for
ovarian conservation in premenopausal women at high risk. Bilat-
eral salpingo-oophorectomy is, however, associated with multiple
physiological and psychosocial side effects that may contribute to
a decrease in the quality of life and a loss of fertility in younger
women. Consequently, the use of endometrial cytological testing
in high-risk women or improved in vivo imaging devices (i.e.,
confocal microlaparoscopes, photoacoustic imaging, µCT, and
contrast enhanced 3D Doppler sonography) could prove to be
more effective for both early detection and treatment. In addition,
alternative strategies for tumor-specific imaging, which involve the
use of FR-α-targeted fluorescent agents, HER-2-targeted magnetic
iron oxide nanoparticles, or protease-specific NIRF probes, merit
further investigation as selective tools for early tumor detection,
monitoring, and image-guided surgery. It is worth noting that
animal models are a valuable tool in ovarian cancer research for
the purpose of developing and testing novel imaging technolo-
gies, biomarkers, and experimental treatments. However, there are
currently a limited number of animal models available for HGSC.
Advances in tumor xenograft technologies have enabled the devel-
opment of personalized avatar mouse models, which have emerged
as an ideal drug-testing platform, especially in concurrent clini-
cal trials. Additionally, tumorgrafts appear to have qualities well
suited to model HGSC. We suggest that avatars have the potential
to improve patient outcome and quality of life by reducing the cost
and toxicity of ineffective imaging and treatment.
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